淋巴细胞恶性瘤在阿塔克西亚-Telangiectasia:与新的向治疗的经验
Samanta Catueno1, Ramya Ramakrishnan1, Sarah Elitzur2,3
1Department of Pediatrics, Pediatric Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pediatric blood & cancer
|July 3, 2025
概括
患有 - 脑膜异位症 (AT) 的患者需要新的癌症治疗方法. 针对性疗法如易布鲁替尼,阿勒姆图祖马布和威尼托克拉克斯在AT患者的淋巴细胞恶性瘤中表现有前途,改善了毒性较小的结果.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
背景情况:
- 在淋巴细胞恶性瘤治疗中,阿塔克西亚 - 端膜炎症 (AT) 患者存在独特的挑战.
- 对化疗和辐射的敏感性增加需要替代治疗策略.
研究的目的:
- 提出成功的向疗法整合在AT患者有淋巴细胞恶性瘤的案例.
- 突出针对性药物的潜力,以改善结果并最大限度地降低毒性.
主要方法:
- 一系列病例报告详细介绍了三名患有淋巴细胞恶性瘤的AT患者的治疗方法.
- 使用的向疗法:易布鲁替尼用于扩散性大B细胞淋巴瘤,阿莱姆图祖马布用于T细胞前淋巴细胞白血病,维尼托克拉克斯用于早期T细胞前体急性淋巴细胞白血病.
主要成果:
- 在所有三个案例中都证明了针对性代理的成功结果.
- 与传统化疗和放射治疗相比,观察到最小的毒性.
结论:
- 向疗法为AT患者的淋巴细胞恶性瘤提供了一种可行且不太有毒的治疗选择.
- 进一步的研究对于优化这种高风险人群的个性化治疗方法至关重要.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
667
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
667
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K